Summary:
In a study published in Cell, researchers at Gladstone Institutes have created the first comprehensive atlas of circulating blood proteins that cross the blood-brain barrier into the brain. Led by Dr. Andrew Yang, the team deployed Nobel Prize-winning protein-labeling chemistry to track 861 plasma proteins in mice, finding that the blood-brain barrier selectively imports just 92, most originating in distant organs like the liver.
In preclinical models of Alzheimer’s disease, researchers discovered that before the barrier physically degrades and leaks toxins, it first shuts down the import of critical protective proteins, such as liver-derived apolipoprotein A1 (APOA1). Boosting systemic APOA1 restored neuronal connectivity and halted disease progression, demonstrating that neurodegeneration may begin when the brain’s peripheral molecular supply line is severed.
Key Facts:
- First Blood-to-Brain Protein Atlas: Out of 861 circulating plasma proteins tracked, the blood-brain barrier selectively imports exactly 92, operating as an intelligent gatekeeper rather than a simple passive filter.
- Molecular “ZIP Code” System: Transported proteins are directed to specific neural target cells; for instance, liver-derived APOA1 specifically targets astrocytes to preserve synaptic connections between neurons.
- Early Transport Failure in Alzheimer’s: In Alzheimer’s mouse models, the blood-brain barrier stops importing protective proteins like APOA1 well before it begins physically leaking harmful substances, revealing that early pathology involves supply-line failure rather than just barrier breakdown.
Source: Gladstone Institutes / Cell
For more than a century, neuroscientists have viewed the blood-brain barrier (BBB) primarily as a physiological fortress: a tight seal of endothelial cells, pericytes, and astrocytic end-feet designed to keep pathogens, peripheral immune cells, and toxic macromolecules out of delicate cerebral tissue.
However, this fortress model fails to explain how the brain monitors systemic physiology or obtains essential large-molecule signals generated by peripheral organs like the liver and kidneys.
In a landmark study published in the journal Cell, researchers at Gladstone Institutes overturn this one-way defensive paradigm. Led by Gladstone Investigator Dr. Andrew Yang, the team mapped the first comprehensive atlas of blood-borne proteins transported across the blood-brain barrier into the mammalian brain.
Their findings reveal that the BBB functions as a selective molecular transfer hub, using specialized receptors to sample plasma proteins from distant bodily organs and direct them to specific brain cells using an intrinsic molecular “ZIP code” system.
Critically, the research demonstrates that in Alzheimer’s disease, this supply line breaks down long before the barrier becomes physically porous, opening therapeutic strategies aimed at treating neurodegeneration from the outside in.
Decoding the Brain-Body Dialogue
Different visceral organs continuously secrete cocktails of signaling proteins into blood plasma to reflect systemic metabolic states. Yet, identifying which of these proteins cross intact cerebral vessels without disrupting normal vascular physiology has historically proven technically impossible.
To solve this, Yang’s team utilized bioorthogonal, click-chemistry protein-labeling strategies to tag the entire mouse plasma proteome without altering biological binding properties.
After infusing labeled plasma proteins back into the circulation of mice, the researchers analyzed cerebral tissue to map which molecules successfully traversed the barrier:
- Strict Gatekeeping: Out of 861 tracked plasma proteins, only 92 crossed the blood-brain barrier into the brain parenchyma.
- Distant Origins: The vast majority of imported proteins were synthesized not within the nervous system, but by peripheral tissues, predominantly the liver.
- Targeted Cellular Routing: Once inside the brain, imported proteins did not diffuse indiscriminately. Instead, specific proteins homed to designated cellular compartments, such as microglia, neurons, or astrocytes, carrying out distinct physiological duties.
“We think of blood proteins as messengers carrying signals from distant body parts, and the cells of the blood-brain barrier import only the ones the brain really needs,” explained first author Dr. Haoyue Zhou, a postdoctoral fellow in Yang’s laboratory. “It’s like a molecular ZIP code system that helps each protein reach its intended destination.”
A prime example identified in the atlas is apolipoprotein A1 (APOA1). Synthesized predominantly by hepatocytes in the liver, APOA1 travels through the circulation, crosses the BBB, and targets astrocytes. Once bound, it activates signaling cascades required to maintain synaptic density and stabilize neuronal connectivity.
“For a century, we’ve treated the blood-brain barrier as a simple physical boundary protecting the brain from toxins,” said Dr. Yang, assistant professor of neurology at the University of California, San Francisco (UCSF) and investigator at Gladstone. “We’re finding that it’s an intelligent interface that plucks the right proteins in the blood, often from distant parts of the body, and delivers them to the right cell types in the brain. Brain health depends on this sophisticated molecular supply line from the body.”
A Reversal in Alzheimer’s Pathology
The team next tracked this transport machinery across the lifespan in mouse models of Alzheimer’s disease.
The prevailing view in neurovascular research holds that Alzheimer’s progression causes the blood-brain barrier to physically disintegrate, opening tight junctions and allowing toxic albumin and fibrinogen to flood the parenchyma, sparking neuroinflammation.
However, Yang and Zhou discovered that an opposing failure occurs first:
- Early Import Shutdown: Well before tight junctions degrade or blood vessels become leaky, the BBB selectively terminates the active transport of neuroprotective molecules, including liver-derived APOA1.
- Synaptic Erosion: Starved of protective peripheral signals, astrocytes fail to maintain synaptic integrity, leading to dendritic spine loss, circuit dysfunction, and early behavioral deficits.
- Late Barrier Breakdown: Only after prolonged transport starvation does the anatomical structure of the barrier collapse, permitting toxic peripheral influx.
“Before the barrier starts leaking harmful proteins into the brain, it stops letting the beneficial ones through,” Zhou noted. “The brain’s supply line from the body starts to fail.”
Rescuing the Brain from the Outside In
To test whether replenishing these lost peripheral signals could counteract neurodegeneration, the researchers engineered Alzheimer’s mouse models to overexpress human APOA1 specifically in their liver tissue.
As circulating levels increased, more APOA1 crossed the blood-brain barrier into the central nervous system. The influx of liver-derived APOA1 restored astrocytic support, preserved synaptic connectivity, and reduced cognitive and behavioral signs of Alzheimer’s disease.
“Alzheimer’s disease may not start entirely inside the brain; it may start when the brain’s supply line from the body is severed,” Yang concluded. “If that’s right, we may be able to fight this disease from outside the brain, by restoring what the brain has lost.”
The identification of this 92-protein atlas provides dual translational opportunities. First, clinicians could potentially treat cognitive decline by pharmacologically boosting protective protein production in peripheral organs like the liver. Second, by mapping the precise endogenous receptors used by these 92 proteins, bioengineers can design targeted “molecular shuttles” that piggyback life-saving therapeutics across the blood-brain barrier directly to diseased brain cells.
Questions and Answers
What is the new blood-brain barrier protein atlas?
It is the first comprehensive molecular catalog of circulating blood proteins that are actively transported across the blood-brain barrier into the brain. Created by Gladstone Institutes researchers, the atlas identifies 92 specific plasma proteins (out of 861 tracked) that cross into the brain, primarily originating in peripheral organs such as the liver.
How does the “molecular ZIP code” system work?
The blood-brain barrier does not allow imported proteins to float around randomly. Once proteins cross the barrier, specialized molecular guidance cues direct them to specific cell types (such as astrocytes, neurons, or microglia) where they perform essential maintenance, such as protecting synaptic connections.
How does this discovery change our understanding of Alzheimer’s disease?
Scientists previously believed the blood-brain barrier’s primary fault in Alzheimer’s was becoming physically leaky. This study shows that before it ever leaks, the barrier stops importing vital protective proteins like APOA1 from the liver. Restoring these peripheral proteins reversed early signs of the disease, proving that neurodegeneration can be combated by repairing the body-to-brain supply line.
Funding: The work was supported by the National Institutes of Health (DP5OD033381), National Institute of Neurological Disorders and Stroke (1R01NS128909, 1RF1NS139975), Alzheimer’s Association (ADSF-24-1345199-C), Burroughs Wellcome Fund, the Ludwig Family Foundation, the Dolby Family, UC San Francisco, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the National Institute of General Medical Sciences, the Larry L. Hillblom Foundation (2023-A-020-FEL), the National Science Foundation, and the NOMIS Foundation.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this Alzheimer’s disease Research:
- Media Contact: Julie Langelier
- Source: Gladstone Institutes
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: Cell (Nov 11, 2026). “The blood-brain barrier imports diverse neuroprotective proteins through path-ways impaired early in Alzheimer’s disease models.” Authors: Haoyue Zhou, Jason C. Maynard, Alexander J. Pennacchio, Amanda Apolonio, Xi Liu, Lei Yao, Mina Negahban, Zimo Zhang, Bella Ding, Jane Oberhauser, Xinlan Wen, Myung Jin Yang, Fionna Huang, Yuichi Chayama, Sahith Doddipalli, Mylinh Bernardi, Lane Domke, Iris Lo, Jeffrey Simms, Andrew Pan, Sining Du, Ning-Sum To, Pui Shuen Wong, Duc Duong, Eddie Fox, Nicholas T. Seyfried, Tom H. Cheung, Tara E. Tracy, Alma L. Burlingame, and Andrew C. Yang.
- DOI: 10.1016/j.cell.2026.10.039
Abstract
The blood-brain barrier imports diverse neuroprotective proteins through path-ways impaired early in Alzheimer’s disease models
The blood-brain barrier (BBB) has been defined primarily by what it excludes, yet the scale and function of physiological blood-to-brain protein transport remain largely unknown. Using bioorthogonal proteomics, we find that the healthy BBB samples 191 plasma proteins and permits 92 into the brain parenchyma.
Enriched for carrier and metabolic functions, these proteins home to distinct brain cell types, such as apolipoprotein A1 (APOA1) to astrocytes and alpha-1 antitrypsin (SERPINA1) to microglia.
This cell-type tropism relies on a BBB-parenchyma receptor hand-off: APOA1 crosses the BBB via SR-B1 and engages astrocytic ATP-binding cassette transporter A1 (ABCA1), a key Alzheimer’s risk gene, driving cholesterol efflux that supports synapse integrity. Unlike LPS-induced nonspecific leakage, early-stage 5xFAD mice show selective BBB transport remodeling, with reduced APOA1 and increased SERPINA1 uptake.
Hepatic APOA1 overexpression restores APOA1 in the 5xFAD brain, rescuing astrocytic, synaptic, and behavioral deficits. These findings recast the BBB as a selective interface that recruits neuroprotective circulatory proteins for brain health.
